Rachel Louise O'Connell

Dr. Rachel Louise O'Connell

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
PKPeey-Sei Kok
Peey-Sei Kok
PBPhilip Beale
Philip Beale
RORachel Louise O'Connell
Rachel Louise O'Connell
PGPeter Grant
Peter Grant
TBTony Bonaventura
Tony Bonaventura
OIon behalf of the PARAGON Investigators
on behalf of the PARAGON Investigators
Kok PS, et al. J Gynecol Oncol. 2018 Aug;30:e86. https://doi.org/10.3802/jgo.2019.30.e86

11 May 2022 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
HFHiba Fatayer
Hiba Fatayer
RORachel Louise O'Connell
Rachel Louise O'Connell
FBFinian Bannon
Finian Bannon
CCCharlotte E Coles
Charlotte E Coles
ECEllen Copson
Ellen Copson
SMStuart A. McIntosh
Stuart A. McIntosh
Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.

20 January 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
AGAmy R. Godden
Amy R. Godden
AMAikaterini Micha
Aikaterini Micha
RORachel Louise O'Connell
Rachel Louise O'Connell
KMKabir Mohammed
Kabir Mohammed
AKAnna M. Kirby
Anna M. Kirby
SWSimon H Wood
Simon H Wood

24 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RORachel Louise O'Connell
Rachel Louise O'Connell
MTMarios Konstantinos Tasoulis
Marios Konstantinos Tasoulis
EHEvguenia Tzvetkova Hristova
Evguenia Tzvetkova Hristova
VTVictoria Teoh
Victoria Teoh
AAAna Agusti
Ana Agusti
GGGerald Gui
Gerald Gui
Incidence of bilateral risk-reducing mastectomies (RRMs) is increasing. The aim of this study was to compare satisfaction, aesthetic and oncological outcomes in women undergoing RRM with implant-based reconstruction comparing nipple-sparing mastectomy (NSM) with skin-sparing mastectomy (SSM) (sacrificing the nipple +/− nipple reconstruction). Women who had undergone bilateral RRM between 1997 and 2016 were invited. Aesthetic outcome and nipple symmetry were evaluated using standardized anthropometric measurements. The oncological outcome was assessed at last documented follow up. Ninety-three women (186 breasts) participated, 60 (64.5%) had NSM, 33 (35.5%) SSM. Median time between surgery and participation was 98.4 months (IQR: 61.7–133.9). Of the women, 23/33 (69.7%) who had SSM underwent nipple reconstruction. Nipple projection was shorter in the reconstructed SSM group than the maintained NSM group (p < 0.001). There was no significant difference in overall symmetry (p = 0.670), satisfaction regarding nipple preservation (p = 0.257) or overall nipple satisfaction (p = 0.074). There were no diagnoses of breast cancer at a median follow up of 129 months (IQR: 65–160.6). Women who undergo nipple-sparing RRM maintain long-term nipple symmetry. Nipple projection was less maintained after nipple reconstruction. Although satisfaction with the nipples was higher in the NSM group, this did not reach statistical significance. No breast cancers developed after RRM with long-term follow up.

13 April 2016 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RORachel Louise O'Connell
Rachel Louise O'Connell
JRJennifer E Rusby
Jennifer E Rusby
GSGregory Fw. Stamp
Gregory Fw. Stamp
ACAnna Conway
Anna Conway
NRNicola Roche
Nicola Roche
GRG.Q. della Rovere
G.Q. della Rovere

1 January 2020 in Journal of Medical Education and Curricular Development
Verified
Journal Article
Open access
PDF file
RORachel Louise O'Connell
Rachel Louise O'Connell
MKMichael T Kemp
Michael T Kemp
HAHasan B. Alam
Hasan B. Alam
The coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on the medical community. It is suspected that the pandemic will impact the medical school application process due to effects on standardized testing, performance measures, financial burdens, and interview strategies. It is important to consider these issues early to optimize success of future strategies and mitigate the impact of COVID-19 on the application cycle.